These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22450396)

  • 41. The prognosis and management of inactive HBV carriers.
    Invernizzi F; Viganò M; Grossi G; Lampertico P
    Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Are serum quantitative hepatitis b surface antigen levels, liver histopathology and viral loads related in chronic hepatitis b-infected patients?
    Balkan A; Namiduru M; Balkan Y; Mete AO; Karaoglan I; Bosnak VK
    Saudi J Gastroenterol; 2016; 22(3):208-14. PubMed ID: 27184639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Relationship among pathological changes in Liver tissues and level of serum HBV DNA, HBeAg and ALT of 194 patients with chronic hepatitis B].
    Zhao DY; Qin YQ; Tang XM; Liu GZ; Zheng W; Nong HR; Song JJ; Xie QY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):35-7. PubMed ID: 17429530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers.
    Ijaz B; Ahmad W; Javed FT; Gull S; Hassan S
    Virol J; 2011 Feb; 8():86. PubMed ID: 21352567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [HBV DNA levels, aminotransferase and histological activity in young male patients with HBeAg positive chronic hepatitis B].
    Cho SC; Lee SH; Shinn JJ; Han SH; Roh BJ; Sohn JH; Lee DH; Kee CS
    Taehan Kan Hakhoe Chi; 2002 Mar; 8(1):44-51. PubMed ID: 12499816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Longitudinal observation of viral load changes in untreated HBeAg negative chronic hepatitis B.
    Croagh CM; Bell SJ; Chen RY; Locarnini S; Desmond PV
    Acta Gastroenterol Belg; 2013 Sep; 76(3):275-81. PubMed ID: 24261020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function.
    Chien TL; Wang JH; Kee KM; Chen CH; Hung CH; Lu SN
    PLoS One; 2016; 11(12):e0166543. PubMed ID: 27935953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
    Bozkaya H; Yurdaydin C; Idilman R; Tüzün A; Cinar K; Erkan O; Bozdayi AM; Erden E; Uzun Y; Cetinkaya H; Uzunalimoglu O
    Antivir Ther; 2005; 10(2):319-25. PubMed ID: 15865226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease.
    Bozkaya H; Bozdayi M; Türkyilmaz R; Sarioglu M; Cetinkaya H; Cinar K; Köse K; Yurdaydin C; Uzunalimoglu O
    Hepatogastroenterology; 2000; 47(36):1675-9. PubMed ID: 11149030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of liver biopsy on the decision to treat patients with chronic hepatitis B genotype D virus infection.
    Al-Qahtani AA; Al-Ashgar HI; Al Mana H; Al-Ahdal MN; Soliman Ali A; Hasanain AF; Helmy A
    Intervirology; 2014; 57(5):248-53. PubMed ID: 24993859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
    Demirören K; Kocamaz H; Doğan Y
    Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
    Jeng WJ; Sheen IS; Chen YC; Hsu CW; Chien RN; Chu CM; Liaw YF
    Hepatology; 2013 Dec; 58(6):1888-96. PubMed ID: 23744454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic carriers of hepatitis B virus in Bangladesh: a comparative analysis of HBV-DNA, HBeAg/anti-HBe, and liver function tests.
    Hasan KN; Rumi MA; Hasanat MA; Azam MG; Ahmed S; Salam MA; Islam LN; Hassan MS
    Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):110-7. PubMed ID: 12118438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication.
    Praneenararat S; Chamroonkul N; Sripongpun P; Kanngurn S; Jarumanokul R; Piratvisuth T
    BMC Gastroenterol; 2014 Dec; 14():218. PubMed ID: 25523185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell volume.
    Ke WM; Xie SB; Li XJ; Zhang SQ; Lai J; Ye YN; Gao ZL; Chen PJ
    J Viral Hepat; 2011 Sep; 18(9):637-45. PubMed ID: 21794025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
    Lampertico P; Del Ninno E; Manzin A; Donato MF; Rumi MG; Lunghi G; Morabito A; Clementi M; Colombo M
    Hepatology; 1997 Dec; 26(6):1621-5. PubMed ID: 9398007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of liver biopsy in Egyptian HBeAg-negative chronic hepatitis B patients at initial presentation: implications for therapy.
    El-Zayadi AR; Badran HM; Saied A; Shawky S; Attia Mel-D; Zalata K
    Am J Gastroenterol; 2009 Apr; 104(4):906-11. PubMed ID: 19293791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers.
    Maimone S; Calvaruso V; Pleguezuelo M; Squadrito G; Amaddeo G; Jacobs M; Khanna P; Raimondo G; Dusheiko G
    J Viral Hepat; 2009 Nov; 16(11):769-74. PubMed ID: 19709363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.